title: Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study.
abstract: The efficacy and safety of the long-acting repeatable formulation of octreotide (OCT-LAR) treatment in patients suffering from acromegaly was investigated retrospectively in Shizuoka prefecture, Japan. Thirty patients (11 male, 19 female; average age, 48.9 years old), 29 of whom had undergone transsphenoidal surgery previously, were treated with OCT-LAR. OCT-LAR was injected i.m. every 4 weeks with an intended protocol of 20 mg over 24 months, however, 46.7% of patients required the dose of OCT-LAR to be increased. The final average dose of OCT-LAR was 25.0 +/- 6.8 mg. Administering OCT-LAR significantly decreased serum GH and insulin-like growth factor 1 (IGF-1) levels (from 13.7 +/- 11.9 to 5.8 +/- 7.3 microg/L and from 585 +/- 263 to 339 +/- 193.7 microg/L after 3 months, respectively). Among patients treated with OCT-LAR, 56.7% expressed <or=2.5 microg/L serum GH and 53.3% displayed serum IGF-1 levels within the normal range, while 36.7% met both criteria that indicated treatment success. A sufficient outcome was achieved in 73.3% of patients when the rate of GH <or=2.5 microg/L or normalization of IGF-1 was accumulated. OCT-LAR did not have a negative effect on glucose tolerance when hemoglobin A1c was used as a marker. A gallbladder polyp was found only in 1 patient but it was uncertain whether OCT-LAR was involved in its development because the patient was not examined before OCT-LAR treatment. There were no abnormalities on liver function tests in any patients. In conclusion, our results showed that OCT-LAR was safe and effective as a therapeutic option for Japanese patients with acromegaly in a postoperative setting, by controlling the disease activity.
authors.affiliation: Second Division, Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. okitaka@hama-med.ac.jp
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Oki
authors.forename: Tatsuhide
authors.initials: T
authors.lastname: Inoue
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Imura
authors.forename: Tokutaro
authors.initials: T
authors.lastname: Tanaka
authors.forename: Rieko
authors.initials: R
authors.lastname: Genma
authors.forename: Masayasu
authors.initials: M
authors.lastname: Iwabuchi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hataya
authors.forename: Yuji
authors.initials: Y
authors.lastname: Matsuzawa
authors.forename: Kazumi
authors.initials: K
authors.lastname: Iino
authors.forename: Shigeru
authors.initials: S
authors.lastname: Nishizawa
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Nakamura
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000209:etiology; D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D005877:Gigantism / Q000188:drug therapy*; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000150:complications / Q000601:surgery; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000037:antagonists & inhibitors* / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007564:Japan; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000150:complications / Q000601:surgery; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003692:Delayed-Action Preparations; D006727:Hormone Antagonists; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D015282:Octreotide